"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 3 | 5 |
| 1999 | 4 | 3 | 7 |
| 2000 | 1 | 4 | 5 |
| 2001 | 5 | 7 | 12 |
| 2002 | 1 | 6 | 7 |
| 2003 | 6 | 5 | 11 |
| 2004 | 3 | 8 | 11 |
| 2005 | 7 | 11 | 18 |
| 2006 | 9 | 8 | 17 |
| 2007 | 16 | 4 | 20 |
| 2008 | 21 | 11 | 32 |
| 2009 | 17 | 12 | 29 |
| 2010 | 13 | 9 | 22 |
| 2011 | 20 | 22 | 42 |
| 2012 | 18 | 8 | 26 |
| 2013 | 13 | 10 | 23 |
| 2014 | 14 | 19 | 33 |
| 2015 | 22 | 13 | 35 |
| 2016 | 16 | 17 | 33 |
| 2017 | 12 | 14 | 26 |
| 2018 | 23 | 12 | 35 |
| 2019 | 15 | 15 | 30 |
| 2020 | 20 | 12 | 32 |
| 2021 | 30 | 21 | 51 |
| 2022 | 2 | 24 | 26 |
| 2023 | 2 | 7 | 9 |
| 2024 | 21 | 12 | 33 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10).
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct; 8:e2400477.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.
-
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. J Comp Eff Res. 2024 Oct; 13(10):e240111.
-
PIK-III exerts anti-fibrotic effects in activated fibroblasts by regulating p38 activation. PLoS One. 2024; 19(9):e0306624.
-
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 Sep; 8:e2400418.
-
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. Elife. 2024 Aug 30; 13.
-
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Adv. 2024 08 13; 8(15):4209-4220.
-
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024 Sep 20; 42(27):3187-3195.